Tivdak
Tivdak is the brand name for tisotumab vedotin, an antibody-drug conjugate developed by Seagen. It targets tissue factor (TF), a protein overexpressed in many solid tumors, including cervical cancer. The drug combines a human monoclonal antibody against TF with MMAE, a cytotoxic agent that disrupts microtubules, connected by a protease-cleavable linker. After binding TF on tumor cells, Tivdak is internalized and MMAE is released inside the cell, inhibiting tubulin polymerization and triggering cell death. TF is also present in tumor vasculature, potentially enabling broader anti-tumor effects.
Indications and usage: In the United States, Tivdak was approved for adults with recurrent or metastatic cervical
Administration and dosing: Tivdak is given as an intravenous infusion every three weeks. Treatment continues until
Safety: Common adverse events include fatigue, nausea, decreased appetite, and ocular events such as keratopathy or
Research: Investigational in other TF-expressing tumors, with ongoing trials evaluating efficacy in additional cancers and in